Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells

@article{Thurnher2003BetulinicAA,
  title={Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells},
  author={Dietmar Thurnher and Dritan Turhani and Martina Pelzmann and Bettina Wannemacher and Birgit Knerer and Michael Formanek and Volker Wacheck and Edgar Selzer},
  journal={Head \& Neck},
  year={2003},
  volume={25}
}
A new compound, betulinic acid, has been found to be cytotoxic against a variety of tumor cells originating from the neural crest. Its efficacy against head and neck squamous cellular carcinoma cell lines has so far not been tested. 

Targeting Cancer by Betulin and Betulinic Acid

Because of their selective cytotoxicity against many different tumor cell and their favorable therapeutic index, betuline, betulinic acid and many of their derivatives are very promising

Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound

A novel semi‐synthetic betulinic acid‐derived drug candidate well suited for further clinical development is presented.

Betulinic Acid for Cancer Treatment and Prevention

  • S. Fulda
  • Biology, Chemistry
    International journal of molecular sciences
  • 2008
Compounds that exert a direct action on mitochondria present promising experimental cancer therapeutics, since they may trigger cell death under circumstances in which standard chemotherapeutics fail.

Betulinic acid, a natural compound with potent anticancer effects

In-vitro studies have identified this agent as potently effective against a wide variety of cancer cells, also those derived from therapy-resistant and refractory tumors, whereas it has been found to be relatively nontoxic for healthy cells.

Comparision of the Cytotoxic Effects of Birch Bark Extract, Betulin and Betulinic Acid Towards Human Gastric Carcinoma and Pancreatic Carcinoma Drug-sensitive and Drug-Resistant Cell Lines

Comparison of cytotoxic activity of crude birch bark extract and purified betulin and betulinic acid towards human gastric carcinoma and human pancreatic carcinoma cell lines shows significant differences in sensitivity between cell lines depending on the compound used, and suggests that both betulin And betulin can be considered as a promising leads in the treatment of cancer.

Betulinic Acid a Radiosensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines

It could be shown that betulinic acid alone inhibits cell survival, affects cell survival additively in combination with irradiation and decreases clonogenic survival in both cell lines when applied alone.

Betulinic acid: a natural product with anticancer activity.

  • S. Fulda
  • Biology, Chemistry
    Molecular nutrition & food research
  • 2009
In contrast to the potent cytotoxicity of BA against a variety of cancer types, nonmalignant cells and normal tissue remained relatively resistant to BA, indicating a therapeutic window.

Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy

Recent advances in research into anticancer activity of BetA are discussed, including relevant modes of delivery, and the agent's therapeutic efficacy, mechanism of action, and future perspective as a pipeline anticancer drug.

Targeting mitochondrial apoptosis by betulinic acid in human cancers.

...

References

SHOWING 1-10 OF 18 REFERENCES

Betulinic acid: A new cytotoxic agent against malignant brain‐tumor cells

Findings suggest that Bet A may be a promising new agent for the treatment of medulloblastomas and glioblastoma cells that clearly warrants further pre‐clinical and clinical evaluation.

Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis

As a result of bioassay–guided fractionation, betulinic acid, a pentacyclic triterpene, was identified as a melanoma–specific cytotoxic agent and antitumour activity was mediated by the induction of apoptosis.

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.

Effects of betulinic acid alone and in combination with irradiation in human melanoma cells.

The strictly additive mode of growth inhibition in combination with irradiation suggests that the two treatment modalities may function by inducing different cell death pathways or by affecting different target cell populations.

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

  • C. JacobsG. Lyman L. Schacter
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve and patients with better PS and poorly differentiated tumors had superior survival.

Head and neck cancer.

  • S. Taylor
  • Medicine
    Cancer chemotherapy and biological response modifiers
  • 1991
Head and Neck Cancer addresses a wide range of topics under the broad heading of head and neck oncology, and includes articles on IMRT, combined modality treatments, the use of targeted agents in conjunction with chemotherapy, the Use of transoral robotic surgery followed by postoperative radiation therapy, and theUse of particle therapy.

Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

It is demonstrated that a temperature-sensitive p53 induces temperature-dependent decreases in the expression of the apoptosis-suppressing gene bcl-2 in the murine leukemia cell M1, while simultaneously stimulating increases in theexpression of bax, a gene which encodes a dominant-inhibitor of the Bcl-1 protein.

BCL-2 family members and the mitochondria in apoptosis.

As the BCL-2 family members reside upstream of irreversible cellular damage and focus much of their efforts at the level of mitochondria, they play a pivotal role in deciding whether a cell will live or die, and it is argued that the amphipathic a-helical BH3 domain serves as a critical death domain in the pro-apoptotic members.